ISSN: 1300-7777 E-ISSN: 1308-5263
Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia [Turk J Hematol]
Turk J Hematol. 2013; 30(2): 211-213 | DOI: 10.4274/Tjh.2012.0013  

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Ahmet Emre Eşkazan1, Teoman Soysal2
1Diyarbakır Training And Research Hospital, Department Of Hematology, Diyarbakır, Turkey
2İstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, Turkey



Dasatinib F317L BCR-ABL Mutasyonu Olan Kronik Miyeloid Lösemi Hastalarında Etkili Olabilir

Ahmet Emre Eşkazan1, Teoman Soysal2
1Diyarbakır Eğitim Ve Araştırma Hastanesi, Hematoloji Bölümü, Diyarbakır, Türkiye
2İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Hematoloji Bölümü, İstanbul, Türkiye



Ahmet Emre Eşkazan, Teoman Soysal. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia. Turk J Hematol. 2013; 30(2): 211-213

Corresponding Author: Ahmet Emre Eşkazan, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686